𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Carcinoembryonic antigen in carcinoma of the uterine cervix 2. Tissue localization and correlation with plasma antigen concentration

✍ Scribed by J. R. Van Nagell Jr.; E. S. Donaldson; E. C. Gay; S. Hudson; R. M. Sharkey; F. J. Primus; D. F. Powell; D. M. Goldenberg


Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
396 KB
Volume
44
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Immunoperoxidase staining for carcinoembryonic antigen (CEA) was performed on the tumors of 241 patients with invasive carcinoma of the cervix. Positive tissue staining indicative of a CEA concentration of at least 3 pg/gm was present in 154 tumors (63%) as opposed to 0 of 30 specimens of normal cervix (p < .001). Plasma CEA values were obtained at the time of tissue staining on all patients. Plasma CEA concentration was related more directly to total tumor burden (tumor CEA content X extent of disease) than to tumor CEA concentration alone. Progressively rising plasma CEA levels predicted recurrent disease in over 80% of patients whose tumors stained positively for CEA. In contrast, serial plasma CEA values correlated positively with clinical disease status in only 28% of patients whose tumors were devoid of CEA. Immunoperoxidase staining of tissue specimens identifies those patients whose tumors contain high levels of CEA and who therefore should benefit most from subsequent plasma antigen determinations.

Cancer 44:944-948, 1979.


πŸ“œ SIMILAR VOLUMES


Serum concentrations of squamous-cell ca
✍ Lukas Hefler; Katrin Frischmuth; Georg Heinze; Gerhard Sliutz; Sepp Leodolter; A πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 42 KB πŸ‘ 2 views

Our aim was to evaluate the clinical usefulness of serum concentrations of squamous-cell carcinoma antigen (SCC-Ag) and tissue polypeptide antigen (TPA) in the follow-up of patients with vulvar cancer. We measured SCC-Ag and TPA in 480 serum samples of 82 patients with squamous-cell vulvar cancer. R

Phase I/II trial of 131I-MN-14 F(ab)2 an
✍ Malik E. Juweid; George Hajjar; Lawrence C. Swayne; Robert M. Sharkey; Samer Sul πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 464 KB πŸ‘ 1 views

## BACKGROUND. Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131 I-MN-14 F(ab